Lyra Therapeutics Q3 net loss $11.9M; ENLIGHTEN 2 topline due Q2 2025

Lyra Therapeutics, Inc.

2024-Q3 EPS reported -$1.27 revenue$1,325,000

Cash & equivalents $51.6M as of Sep 30, 2024; runway into Q1 2026.
R&D expenses fell to $5.9M from $12.4M YoY; G&A down to $3.9M from $5.0M.
ENLIGHTEN 2 pivotal trial fully enrolled Oct 2024; topline results expected Q2 2025.
ENLIGHTEN 1 extension study showed no product-related serious adverse events.
Net loss improved to $11.9M vs $15.7M in Q3 2023.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.